KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Idexx Laboratories (IDXX) EBITDA Margin (2016 - 2025)

Idexx Laboratories has reported EBITDA Margin over the past 17 years, most recently at 28.94% for Q4 2025.

  • Quarterly results put EBITDA Margin at 28.94% for Q4 2025, up 152.0% from a year ago — trailing twelve months through Dec 2025 was 31.6% (up 265.0% YoY), and the annual figure for FY2025 was 31.6%, up 265.0%.
  • EBITDA Margin for Q4 2025 was 28.94% at Idexx Laboratories, down from 32.11% in the prior quarter.
  • Over the last five years, EBITDA Margin for IDXX hit a ceiling of 33.62% in Q2 2025 and a floor of 20.81% in Q2 2022.
  • Median EBITDA Margin over the past 5 years was 29.88% (2022), compared with a mean of 29.25%.
  • Biggest five-year swings in EBITDA Margin: plummeted -1057bps in 2022 and later soared 1058bps in 2023.
  • Idexx Laboratories' EBITDA Margin stood at 24.86% in 2021, then increased by 10bps to 27.34% in 2022, then dropped by 0bps to 27.21% in 2023, then increased by 1bps to 27.42% in 2024, then increased by 6bps to 28.94% in 2025.
  • The last three reported values for EBITDA Margin were 28.94% (Q4 2025), 32.11% (Q3 2025), and 33.62% (Q2 2025) per Business Quant data.